Cargando…

Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features

OBJECTIVE: To report the experience of a single center for the selection of radioiodine-refractory (RAIR) thyroid cancer patients (RAIR-TC) who needed tyrosine kinase inhibitor (TKIs) treatment. PATIENTS AND METHODS: We evaluated all features of 279 RAIR-TC patients both at the time of diagnosis and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorusso, L., Minaldi, E., Esposito, G., Piaggi, P., Bottici, V., Brogioni, S., Giani, C., Valerio, L., Molinaro, E., Elisei, R., Agate, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514097/ https://www.ncbi.nlm.nih.gov/pubmed/37084131 http://dx.doi.org/10.1007/s40618-023-02076-6

Ejemplares similares

Thyroid cancer and COVID-19: experience at one single thyroid disease referral center
por: Prete, Alessandro, et al.
Publicado: (2021)

Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response
por: Campopiano, Maria Cristina, et al.
Publicado: (2023)

Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma
por: Minaldi, Elisa, et al.
Publicado: (2023)

Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test
por: Valerio, L., et al.
Publicado: (2023)

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities
por: Lorusso, Loredana, et al.
Publicado: (2021)

Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates
por: Lorusso, L., et al.
Publicado: (2021)

MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients
por: Valerio, Laura, et al.
Publicado: (2020)

Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer
por: Puleo, Luciana, et al.
Publicado: (2022)

Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment
por: Viola, David, et al.
Publicado: (2018)

OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma
por: Matrone, Antonio, et al.
Publicado: (2020)

Nutrition in Advanced Thyroid Cancer Patients
por: Agate, Laura, et al.
Publicado: (2022)

MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children
por: Prete, Alessandro, et al.
Publicado: (2020)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia
por: Prete, Alessandro, et al.
Publicado: (2021)

Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations
por: Elisei, Rossella, et al.
Publicado: (2019)

MON-495 Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma
por: Viola, Nicola, et al.
Publicado: (2020)

Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma
por: Matrone, Antonio, et al.
Publicado: (2020)

Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs
por: Prete, Alessandro, et al.
Publicado: (2021)

Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?
por: Campopiano, Maria Cristina, et al.
Publicado: (2021)

RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency
por: Ramone, Teresa, et al.
Publicado: (2020)

Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination
por: Valerio, Laura, et al.
Publicado: (2023)

Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance
por: Ghirri, Arianna, et al.
Publicado: (2023)

Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience
por: Romei, Cristina, et al.
Publicado: (2018)

Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA
por: Wagner, Monika, et al.
Publicado: (2017)

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
por: Mu, Zhuan-Zhuan, et al.
Publicado: (2019)

Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC)
por: Lodi Rizzini, Elisa, et al.
Publicado: (2021)

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
por: Wong, Selina K., et al.
Publicado: (2019)

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
por: Liu, Jierui, et al.
Publicado: (2019)

Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
por: Sondorp, Luc H.J., et al.
Publicado: (2020)

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer
por: Fordham, Beth A, et al.
Publicado: (2015)

SAT520 Efficacy of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers
por: Toro-Tobon, David, et al.
Publicado: (2023)

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
por: McFarland, Daniel C, et al.
Publicado: (2014)

The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
por: Al-Kuraya, Khawla Sami, et al.
Publicado: (2021)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
por: Schmidt, Angelica, et al.
Publicado: (2017)

Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis
por: Wang, Chen, et al.
Publicado: (2017)

Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers
por: Oh, Ji Min, et al.
Publicado: (2022)

Linking iodine with autoimmune thyroiditis.
por: Rose, N R, et al.
Publicado: (1999)

Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death
por: Wächter, Sabine, et al.
Publicado: (2018)

BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review
por: Matrone, Antonio, et al.
Publicado: (2023)

Effect of monocarboxylate transporter-1 on the biological behavior of iodine-refractory thyroid carcinoma
por: Li, Qian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gtk8jf5f2rvuubijll80rejrui